Table 1. Summary of SUSD2 staining of 175 breast cancer patient samples.
| 175 Tumors Total | No SUSD2 Staining 0 | Weak SUSD2 Staining 1+ | Moderate SUSD2 Staining 2+ | Strong SUSD2 Staining 3+ | aModerate + Strong |
|---|---|---|---|---|---|
| Invasive (n = 133) | 8% (11) | 13% (17) | 41% (55) | 38% (50) | 79% |
| in situ (n = 42) | 7% (3) | 12% (5) | 48% (20) | 33% (14) | 81% |
| ER+ (n = 145) | 9% (13) | 14% (20) | 42% (61) | 35% (51) | 77% |
| PR+ (n = 123) | 9% (11) | 14% (17) | 45% (55) | 32% (40) | 77% |
| HER-2+ (n = 32) | 3% (1) | 6% (2) | 38% (12) | 53% (17) | 91% |
| Triple Negative (n = 15) | 7% (1) | 13% (2) | 20% (3) | 60% (9) | 80% |
| LN Involvement (n = 45) | 2% (1) | 18% (8) | 38% (17) | 42% (19) | 80% |
IHC analysis was performed using an anti-SUSD2 antibody on 175 patient breast tumors representing the following subtypes: invasive, in situ, ER positive, PR positive, HER-2 amplification, triple negative and lymph node (LN) involvement. The number of tumors is each group is indicated by parentheses. Tumors were placed into groups according to SUSD2 staining score, 0, 1+, 2+ and 3+. The percentage of tumors stained is indicated.
aThe percentage of tumors with moderate (2+) SUSD2 staining plus strong (3+) SUSD2 staining.